The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| NEO | -21.99% | -83.79% | -30.49% | +229% |
| S&P | +19.17% | +69.21% | +11.09% | +480% |
NeoGenomics is a provider of genetic testing, specializing in cancer diagnostics.
The company released promising earnings results.
The cancer screening company showed its turnaround may be working.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $190.17M | 10.6% |
| Gross Profit | $75.71M | 9.9% |
| Gross Margin | 39.81% | -0.2% |
| Market Cap | $1.52B | -28.1% |
| Market Cap / Employee | $608.64K | 0.0% |
| Employees | 2.5K | 13.6% |
| Net Income | -$9,881.00K | 35.5% |
| EBITDA | $5.25M | 81.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $159.62M | -56.5% |
| Accounts Receivable | $159.24M | 5.7% |
| Inventory | 28.6 | 6.8% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $404.68M | 0.9% |
| Short Term Debt | $4.78M | -97.7% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -7.21% | -2.5% |
| Return On Invested Capital | -4.15% | -1.5% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$6,528.00K | -262.9% |
| Operating Free Cash Flow | $1.34M | -86.3% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.35 | 1.06 | 1.16 | 1.81 | -22.19% |
| Price to Sales | 1.80 | 1.36 | 1.40 | 2.08 | -34.43% |
| Price to Tangible Book Value | 30.48 | 27.45 | 35.35 | 76.61 | 35.77% |
| Enterprise Value to EBITDA | -204.60 | -585.25 | 547.11 | 335.50 | -58.09% |
| Return on Equity | -8.6% | -11.8% | -13.0% | -12.4% | 45.50% |
| Total Debt | $604.78M | $411.76M | $410.31M | $409.46M | -32.36% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
